

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Touyun Biotech Group Limited
透雲生物科技集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

VOLUNTARY ANNOUNCEMENT

BUSINESS UPDATE

This is a voluntary announcement of Touyun Biotech Group Limited (the “**Company**” together with its subsidiaries, the “**Group**”).

On 20 November 2024, Shanxi Touyun Biotechnology Co. Ltd.*, a wholly-owned subsidiary of the Group, received the Notice No. 0009 of Wei Shi Xin Zhong Zi [2024] from the National Health Commission (國家衛生健康委員會衛食新終字[2024]第0009號通知) regarding the administrative license application for “Chlamydomonas reinhardtii (white strain)”, which was later renamed to “Chlamydomonas reinhardtii”. This application is substantially equivalent to the Chlamydomonas reinhardtii announced in the National Health Commission’s Announcement No. 2 of 2022 (2022年第2號公告).

Accordingly, Chlamydomonas reinhardtii produced by the Group has expanded into new application scope and area, and has begun to enter the markets of vegan fish, shrimp, and plant-based milk.

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 20 November 2024

* *Direct translation from the Chinese name which is for identification purpose only*

As at the date of this announcement, the Board comprises the following directors:

Executive Directors

Mr. Wang Liang (*Chairman*)

Mr. Du Dong

Non-executive Directors

Mr. Chen Hui

Ms. Tian Yuze

Mr. Zhang Lele

Mr. Jia Wenjie

Independent Non-executive Directors

Mr. Cheung Wing Ping

Mr. Ha Kee Choy Eugene

Mr. To Shing Chuen

Mr. Hu Guohua